期刊文献+

肿瘤坏死因子-α与糖尿病视网膜病变关系的研究进展 被引量:1

Tumor necrosis factor-α and diabetic retinopathy
原文传递
导出
摘要 肿瘤坏死因子(TNF)-α通过其细胞膜上的受体在免疫和非免疫系统中发挥着许多不同作用。研究表明,糖尿病视网膜病变患者血清及玻璃体视网膜局部均可检测到TNF-α,且随病变进展血清中TNF-α水平升高。推测TNF-α可能通过直接损伤血—视网膜屏障,提高视网膜血管通透性,诱导其他细胞因子释放,提高靶细胞的反应性,以及诱导、加重胰岛素抵抗的产生,在糖尿病视网膜病变的发生、发展中起非常重要的作用。 Tumor necrosis factor(TNF)-α exerts numerous functions in the immune and non-immune system through its receptors located on the cellular membrane. Some evidences show that TNF-α is detected in the serum, vitreous body and retina of diabetic patients. Moreover, the levels of TNF-α in the serum step up following the development of diabetic retinopathy(DR). TNF-α might be associated with DR by directly impairing the bloodretinal barriers, promoting retinal vessels' penneabilities, increasing the secretion of other cytokines and their reactivities towards the target cells, inducing and aggravating the insulin resistance, etc.
出处 《国际内分泌代谢杂志》 2006年第6期403-404,411,共3页 International Journal of Endocrinology and Metabolism
关键词 肿瘤坏死因子-Α 糖尿病视网膜病变 血-视网膜屏障 细胞因子 Tumor necrosis factor-α Diabetic retinopathy Blood-retinal barriers Cylokines
  • 相关文献

参考文献18

  • 1Barzilay JI,Abraham L,Heckbert SR,et al.The relation of markers of inflammation to the development of glucose disorders in the elderly:the Cardiovascular Health Study.Diabetes,2001,50:2384-2389.
  • 2Mysliwiec M,Zorena K,Balcerska A.et al.The activity of N-acetyl-betad-glucosaminidase and tumor necrosis factor-alpha at early stage of diabetic retinopathy development in type 1 diabetes mellitus children.Clin Biochem,2006,39:851-856.
  • 3Demircan N,Safran BG,Soylu M.et al.Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy.Eye,2005,[Epub ahead of print].
  • 4韩秀敏,杨文东,曾庆枝,曹相誉.2型糖尿病患者NO、TNF-α浕及其可溶性受体的变化[J].山西医科大学学报,2003,34(5):403-405. 被引量:2
  • 5Joussen AM,Poulaki V,Le ML,et al.A central role for inflammation in the pathogenesis of diabetic retinopathy.FASEB J,2004,18:1450-1452.
  • 6Doganay S,Er H,Evereklioglu C,et al.Comparison of serum NO,TNF-alpha,IL-1beta,IL-2R,IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.Eye,2002,16:163-170.
  • 7甘成,李郑芳,戴丽芬.2型糖尿病视网膜病变者血清TNF-α观察[J].辽宁实用糖尿病杂志,2004,12(2):21-21. 被引量:1
  • 8Takashi Y,Tsugiyasn K,Yasutaka K,et al.Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy.J Diabetes Complications,2001,15:257-259.
  • 9Ben-Mahmud BM,Chan WH,Abdulahad RM,et al.Clinical validation of a link between TNF-alpha and the glycosylation enzyme core 2 GlcNAc-T and the relationship of this link to diabetic retinopathy.Diabetologia,2006,49:2185-2191.
  • 10Chen W,Esselman WJ,Jump DB,et al.Anti-inflammatory effect of docosahexaenoic acid on cytokine-induced adhesion molecule expression in human retinal vascular endothelial cells.Invest Ophthalmol Vis Sci,2005,46:4342-4347.

二级参考文献17

  • 1曹景泰,武丽,张惠蓉,刘宁朴,贺师鹏,陈非.视网膜增殖性疾病玻璃体中胰岛素样生长因子的放射免疫测定[J].中华眼科杂志,1995,31(2):122-125. 被引量:10
  • 2王展,吴敏霞,朱晴晖,刘德琼.老年糖尿病患者免疫功能分析[J].上海免疫学杂志,1995,15(6):372-372. 被引量:12
  • 3赵志勇 王福玉.DM患者血浆ET-1测定及意义[J].上海医学检验杂志,1998,13(4):216-216.
  • 4Zhu M,Ophthal Vis Sci,1999年,40卷,S619页
  • 5Hunt D M,Invest Ophthalmol Vis Sci,1998年,39卷,11期,2111页
  • 6Zhu M,Aust NZJ Ophthalmol,1997年,25卷,增1期,S57页
  • 7Li D Q,Invest Ophthalmol Vis Sci,1996年,37卷,2068页
  • 8张蕙蓉,中华眼底病杂志,1996年,12卷,2期,91页
  • 9Sippy B D,Eye Res,1995年,14卷,495页
  • 10Sun G Y,Progress Brain Res,1995年,105期,231页

共引文献8

同被引文献48

  • 1Anonymous. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number l.Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol, 1985,103 : 1796-1806.
  • 2Entezari M, Ahmadieh H, Dehghan MH, et al. Posterior sub-tenon triamcinolone for refractory diabetic macular edema: a randomized clinical trial. Eur J Ophthalmol,2005,15(6):746- 750.
  • 3Bonini-Filho MA, Jorge R, Barbosa JC, et al. Intravitreal injection versus Sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: A Randomized Clinical Trial. Invest ophthalmol Vis Sci,2005,46:3845-3849.
  • 4Diabetic Retinopathy Clinical Research Network, Chew E, Strauber S,et al. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot Study. Ophthalmolo~,2007, 114:1190-1196.
  • 5Kim SH, Lutz RJ, Wang NS, et ah Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res. 2007,39 : 244-254.
  • 6Schwartz SG, Flynn tfW, Scott IU. Emerging therapies for diabetic macular edema. Expert Rev Ophthalmol,2009,4:163- 171.
  • 7Diabetic Retinopathy Clinical Research Network. A randmnized trial comparing intravitreal triameinolone aeetonide and focal/ grid photoeoagulation for diabetic maeular edema. Ophthalmology, 2008,115 : 1447-1449.
  • 8Diabetic Retinopathy Clinical Research Network, Beck RW, Edwards AIR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol, 2009.127. 245-251.
  • 9Funastu H, Yanashita H, Lkeda T, et ah Angiotensin 1I and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthahnol,2002,133:537-543.
  • 10Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitrealbevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primm7 treatment of diabetic macular edema. Retina,2007,27:1187 - 1195.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部